Skip to main content

Table 2 Other transition probabilities used in model

From: Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis

Treatment independent transitions

Transition

Probability

Source

Inactive carrier to cured

0.020

Shepherd et al. (2006)

Inactive carrier to CHB

0.030

Inactive carrier to CC

0.009

Cured to HCC

0.00005

Zhang et al. (2015)

Inactive carrier to HCC

0.002

CHB to CC

0.010

CHB to HCC

0.004

CHB to Dead

0.009

CC to inactive carrier

0.090

Shepherd et al. (2006)

CC to HCC

0.018

Zhang et al. (2015)

CC to dead

0.025

DC to HCC

0.091

DC to LT Year 1

0.050

HCC to Dead

0.520

Treatment specific other transitions

Transition

Probability for NUCs

Source

CC to DC

0.00936 (RR = 0.36)

Shepherd et al. (2006)

DC to dead

0.052 (RR = 0.50)

LT Year 1 to dead

0.012 (RR = 0.1)

LT Year 2+ to dead

0.0057 (RR = 0.1)

Transition

Probability for BSC

Source

CC to DC

0.026

Zhang et al. (2015)

DC to dead

0.104

LT Year 1 to dead

0.120

LT Year 2+ to dead

0.057

Shepherd et al. (2006)

  1. ADV adefovir dipivoxil, BSC best supportive care, CC compensated cirrohoiss, CHB chronic hepatitis B, DC decompensated cirrhosis, ETV entecavir, HCC hepatocellular carcinoma, LAM lamivudine, LDT telbivudine, LT liver transplant, NUCs nucleos(t)ide analogs, RR relative risk, TDF tenofovir